Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 64

Related Articles by Review for PubMed (Select 15952058)

1.

Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.

Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, Ambrosone CB.

Breast Cancer Res Treat. 2005 Jun;91(3):249-58.

PMID:
15952058
2.

The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.

Fleeman N, Martin Saborido C, Payne K, Boland A, Dickson R, Dundar Y, Fern√°ndez Santander A, Howell S, Newman W, Oyee J, Walley T.

Health Technol Assess. 2011 Sep;15(33):1-102. doi: 10.3310/hta15330. Review.

3.

Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?

Higgins MJ, Rae JM, Flockhart DA, Hayes DF, Stearns V.

J Natl Compr Canc Netw. 2009 Feb;7(2):203-13. Review.

PMID:
19200418
4.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
5.

Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.

Singh MS, Francis PA, Michael M.

Breast. 2011 Apr;20(2):111-8. doi: 10.1016/j.breast.2010.11.003. Epub 2010 Dec 24. Review.

PMID:
21185724
6.

Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?

Zembutsu H, Sasa M, Kiyotani K, Mushiroda T, Nakamura Y.

Expert Rev Anticancer Ther. 2011 Feb;11(2):185-93. doi: 10.1586/era.10.228. Review.

PMID:
21342038
7.
8.

CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.

Higgins MJ, Stearns V.

Curr Oncol Rep. 2010 Jan;12(1):7-15. doi: 10.1007/s11912-009-0076-5. Review.

PMID:
20425602
9.

Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach?

Brauch H, Jordan VC.

Eur J Cancer. 2009 Sep;45(13):2274-83. doi: 10.1016/j.ejca.2009.05.032. Epub 2009 Jul 9. Review.

PMID:
19592233
10.

CYP2D6 and tamoxifen: DNA matters in breast cancer.

Hoskins JM, Carey LA, McLeod HL.

Nat Rev Cancer. 2009 Aug;9(8):576-86. doi: 10.1038/nrc2683. Review.

PMID:
19629072
11.

Tamoxifen metabolism and its effect on endocrine treatment of breast cancer.

Briest S, Stearns V.

Clin Adv Hematol Oncol. 2009 Mar;7(3):185-92. Review.

PMID:
19398943
12.

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.

Lum DW, Perel P, Hingorani AD, Holmes MV.

PLoS One. 2013 Oct 2;8(10):e76648. doi: 10.1371/journal.pone.0076648. eCollection 2013. Review.

13.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

14.

Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer.

Dezentjé VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H.

Clin Cancer Res. 2009 Jan 1;15(1):15-21. doi: 10.1158/1078-0432.CCR-08-2006. Review.

15.

Reducing the risk of late recurrence in hormone-responsive breast cancer.

Cufer T.

Ann Oncol. 2007 Sep;18 Suppl 8:viii18-25. Review.

16.

The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.

Pennery E.

Eur J Oncol Nurs. 2008 Jul;12(3):233-43. doi: 10.1016/j.ejon.2008.01.007. Epub 2008 Mar 26. Review.

PMID:
18372213
17.

CYP2D6 polymorphisms and the impact on tamoxifen therapy.

Beverage JN, Sissung TM, Sion AM, Danesi R, Figg WD.

J Pharm Sci. 2007 Sep;96(9):2224-31. Review.

PMID:
17518364
18.

Factors predictive of response to hormone therapy in breast cancer.

Rastelli F, Crispino S.

Tumori. 2008 May-Jun;94(3):370-83. Review.

PMID:
18705406
19.
20.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk